Original title: Predicting Outcome in the COURAGE Trial. Coronary Anatomy Versus Ischemia. Reference: G. B. John Mancini et al. J Am Coll Cardiol Intv 2013, Article in press. Anatomical risk, ischemic amount or a combination of both, are often factors taken into account for estimating the prognosis or choose a treatment strategy. The COURAGE study (Clinical Outcomes Utilizing...
Longer follow-up registry of angioplasty in left main coronary artery. Significant differences according to the diseased segment.
Original title: The DELTA Registry (Drug-Eluting Stent for Left Main Coronary Artery Disease): A Multicenter registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for left Main Treatment Reference: Naganuma T, et al. J Am Coll Cardiol Intv 2013;6:1242–9 Angioplasty of the unprotected left coronary trunk has increased significantly in recent years showing good results. Currently the...
Unprotected trunk in diabetics: angioplasty with good long-term results but more revascularization
Original title: Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: D-DELTA registry. Reference: Meliga Emanuele, et al. EuroIntervention 2013; 9:803-808 Diabetes increases cardiovascular risk events because of their involvement in diffuse form of the vessels, thereby generating more events and changes in revascularization strategy...
Drug eluting balloon followed BMS versus DES in de novo lesions
Original title: Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial. Reference: Francesco Liistro et al. Am Heart J 2013;166:920-6. Recently, drug eluting balloons (DEB) have emerged as a potential alternative to drug-eluting stents (DES). Paclitaxel is an appropriate drug for DEBs given...
Alvimedica merges with CID, Italy’s leading high tech company specialized in cardiology
Alvimedica fusiona con CID, la empresa líder de alta tecnología italiana especializada en cardiología En línea con su estrategia de convertirse en una de las cinco mayores empresas del mercado mundial en su sector, Alvimedica, exclusivo de la marca en todo el mundo de Turquía en la cardiología intervencionista, se ha fusionado con la innovadora...
Renal angioplasty versus medical treatment, no clinical benefit and only a modest help to control blood pressure
Original title: Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. CORAL trial. Reference: Christopher J. Cooper et al. DOI: 10.1056/NEJMoa1310753 Between 1 and 5% of the hypertensive population has renal artery stenosis and in general, this is combined with peripheral and coronary vascular disease. The renal artery stenosis may result in hypertension, ischemic nephropathy, and multiple long-term...
Infrapatellar balloon angioplasty, the easiest option and with better results in critical ischemia with tissue loss
Original title: Longitudinal outcomes After Tibioperoneal Angioplasty Alone Compared to Tibial Stenting and Atherectomy for Critical Limb ischemia. Reference: Shaun Reynolds et al. Vascular and and Endovascular Surgery 2013 47(7):507-512 The Infrapatellar peripheral vascular disease has increased in recent years, relating to tissue loss and amputation. The therapeutic strategy is not clear, let alone the use of stents...
Clinical factors to help decide between angioplasty and carotid endarterectomy
Original title: A clinical rule (sex, contralateral occlusion, age, and restenosis) to select patients for stenting versus carotid endarterectomy: Systematic review of observational studies with validation in randomized trials. Reference: Touzé E et al. Stroke. 2013;Epub ahead of print Compared with carotid endarterectomy, angioplasty with stent is associated with an increased risk of pre- procedural stroke especially for...
Bivalirudin, effective in the pre-hospitalization phase of infarction
Original title: Bivalirudin Started during Emergency Transport for Primary PCI. Reference: Philippe G. Steg, et;al. NEJM 2013; Octubre 30:1-11 Primary PCI is the preferred treatment for AMI within the first 12 hours of symptom onset and outcomes have been improving with the incorporation of new strategies and technology. This study randomized 2218 STEMI patients started with bivalirudin during...
Low cardiac mortality with bivalirudin beyond the reduction in major bleeding
Original title: Reduction in Cardiac Mortality with Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial. Reference: Gregg W. Stone et al. J Am Coll Cardiol. Epub ahead of print The HORIZONS -AMI study included 3602 patients experiencing ST segment elevation myocardial infarction received primary angioplasty, resulting in lower mortality at 30 days and three years...